BIO survey shows impacts of Biosecure Act

An abrupt shutdown of access to Chinese biotech companies would have devastating impacts on patients and biopharma companies, according to survey results BIO sent to Capitol Hill Wednesday. The survey is intended to help shape the debate over the Biosecure Act (H.R. 7085) and a similar Senate bill, the Prohibiting Foreign Access to American Genetic Information Act (S. 3558).

“We must thoughtfully and over a reasonable period of time work to decouple our dependence and regain U.S. biomanufacturing dominance to advance our national security and public health interests,” BIO President and CEO John Crowley wrote in a message introducing the survey results...